FrancophonIA/ELRC3.0 huggingface dataset:
English: From the three active-comparator studies in patients with symptomatic COPD, the risk of a moderate/severe COPD exacerbation compared with tiotropium was reduced by 50% in one study (HR 0.5; 95% CI: 0.3, 1.0; p=0.044).
Croatian: Od triju ispitivanja s aktivnim usporednim lijekom u bolesnika s KOPB-om, u jednom je ispitivanju primjena lijeka smanjila rizik od umjerenih/teških egzacerbacija KOPB-a za 50% u usporedbi s tiotropijem (HR 0,5; 95% CI: 0,3, 1,0; p=0,044).
English: LAVENTAIR ELLIPTA showed a statistically significant reduction in SGRQ total score compared with tiotropium in one of the three activecomparator studies (see Table 1).
Croatian: ELLIPTA je doveo do statistički značajnog smanjenja ukupnog SGRQ rezultata u usporedbi s tiotropijem u jednom od triju ispitivanja s aktivnim usporednim lijekom (vidjeti Tablicu 1).
English: If you get tightness of the chest, coughing, wheezing or breathlessness immediately after using your LAVENTAIR ELLIPTA inhaler:
Croatian: Ako se javi stezanje u prsima, kašalj, piskanje pri disanju ili nedostatak zraka neposredno nakon primjene lijeka LAVENTAIR ELLIPTA:
English: No dose adjustment is required in patients with mild or moderate hepatic impairment.
Croatian: Oštećenje jetrene funkcije Nije potrebno prilagođavati dozu u bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije.
English: LAVENTAIR ELLIPTA 55/22 micrograms also showed statistically significant improvements compared with placebo in change from baseline in lung volume measures at trough and at 3 hours post dose at Week 12 in the first study (inspiratory capacity: 237 ml and 316 ml respectively, residual volume: -466 ml and -643 ml respectively and functional residual capacity: -351 ml and -522 ml respectively; all p<0.001).
Croatian: U prvom je ispitivanju LAVENTAIR ELLIPTA od 55/22 mikrograma u 12. tjednu pokazao i statistički značajna poboljšanja u usporedbi s placebom s obzirom na promjenu plućnog volumena izmjerenog na kraju intervala doziranja i 3 sata nakon primjene doze u odnosu na početnu vrijednost (udisajni kapacitet: 237 ml odnosno 316 ml, rezidualni volumen: -466 ml odnosno -643 ml i funkcionalni rezidualni kapacitet: -351 ml odnosno -522 ml; p<0,001 za sve).
English: The comparison of FF/UMEC/VI to FF/VI and UMEC/VI resulted in a statistically significant 14.8% reduction in risk of a moderate/severe exacerbation (based on analysis of time to first exacerbation) (Hazard Ratio 0.85; 95% CI: 0.80, 0.91; p<0.001) and 16.0% reduction in risk of a moderate/severe exacerbation respectively (based on analysis of time to first exacerbation) (Hazard Ratio 0.84; 95% CI: 0.78, 0.91; p<0.001).
Croatian: Usporedba FF/UMEC/VI sa FF/VI pokazala je statistički značajno smanjenje rizika od umjerenih/teških egzacerbacija za 14,8% (na temelju analize vremena do prve egzacerbacije) (omjer hazarda 0,85; 95% CI: 0,80, 0,91; p<0,001) i smanjenje rizika od umjerenih/teških egzacerbacija za 16,0% u usporedbi s UMEC/VI (na temelju analize vremena do prve egzacerbacije) (omjer hazarda 0,85; 95% CI: 0,78, 0,91; p<0,001).
English: In one active-comparator study, a higher percentage of patients receiving LAVENTAIR ELLIPTA responded with a clinically meaningful improvement in SGRQ score at Week 24 (53%) compared to tiotropium (46%).
Croatian: U jednom ispitivanju s aktivnim usporednim lijekom, klinički značajno poboljšanje SGRQ rezultata nakon 24 tjedna zabilježeno je kod većeg postotka bolesnika koji su primali LAVENTAIR ELLIPTA (53%) nego kod onih koji su primali tiotropij (46%).
English: In one 6-month Phase III study, LAVENTAIR ELLIPTA demonstrated statistically significant improvements in trough FEV1 (primary endpoint) at Week 24 compared with placebo and each monotherapy component treatment arm.
Croatian: U jednom 6-mjesečnom ispitivanju faze III LAVENTAIR ELLIPTA je nakon 24 tjedna doveo do statistički značajnih poboljšanja najniže vrijednosti FEV1 (primarna mjera ishoda) u usporedbi s placebom i svakom skupinom koja je primala jednu od sastavnica kao monoterapiju.
English: In a 24-week placebo-controlled study in patients with symptomatic COPD, LAVENTAIR ELLIPTA reduced the risk of a moderate/severe COPD exacerbation by 50% compared with placebo (based on analysis of time to first exacerbation: Hazard Ratio (HR) 0.5; 95% CI: 0.3, 0.8; p=0.004*); by 20% compared with umeclidinium (HR 0.8; 95% CI: 0.5, 1.3; p=0.391); and by 30% compared with vilanterol (HR 0.7; 95% CI: 0.4, 1.1; p=0.121).
Croatian: U 24- tjednom placebo kontroliranom ispitivanju u bolesnika s KOPB-om, primjena lijeka LAVENTAIR ELLIPTA smanjila je rizik od umjerenih/teških egzacerbacija KOPB-a za 50% u usporedbi s placebom (na temelju analize vremena do prve egzacerbacije; omjer hazarda (HR) 0,5; 95% CI: 0,3, 0,8; p=0,004∗), za 20% u usporedbi s umeklidinijem (HR 0,8; 95% CI: 0,5, 1,3; p=0,391) te za 30% u usporedbi s vilanterolom (HR 0,7; 95% CI: 0,4, 1,1; p=0,121).
English: In the first study, LAVENTAIR ELLIPTA 55/22 micrograms demonstrated a statistically significant and clinically relevant improvement (based on a minimal clinically important difference (MCID) between 45 to 85 seconds) over placebo in exercise endurance time (EET) obtained 3 hours after dosing at Week 12 (69.4 seconds [p=0.003]).
Croatian: 12. tjednu doveo do statistički značajnog i klinički važnog poboljšanja (na temelju minimalne klinički značajne razlike (MCID) između 45 i 85 sekundi) u odnosu na placebo s obzirom na vrijeme izdržljivosti pri tjelovježbi (engl. exercise endurance time, EET) mjereno 3 sata nakon primjene doze (69,4 sekunde [p=0,003]).
English: LAVENTAIR ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed
Croatian: LAVENTAIR ELLIPTA 55 mikrograma/22 mikrograma prašak inhalata, dozirani
English: Patients with moderate hepatic impairment (Child-Pugh Class B) showed no evidence of an increase in systemic exposure to either umeclidinium or vilanterol (Cmax and AUC) following administration of umeclidinium/vilanterol with umeclidinium at twice the recommended dose and vilanterol at the recommended dose and no evidence of altered protein binding between patients with moderate hepatic impairment and healthy volunteers.
Croatian: U bolesnika s umjerenim oštećenjem jetrene funkcije (Child-Pugh stadij B) nisu pronađeni dokazi povećane sistemske izloženosti ni umeklidiniju ni vilanterolu (Cmax i AUC) nakon primjene doze umeklidinija/vilanterola koja sadrži umeklidinij u dvostruko većoj dozi od preporučene, a vilanterol u preporučenoj dozi, niti dokazi poremećaja u vezanju za proteine u bolesnika s umjerenim oštećenjem jetrene funkcije u odnosu na zdrave dobrovoljce.
English: Multipack: 90 (3 packs of 30) doses
Croatian: Prašak inhalata, dozirani Višestruko pakiranje: 90 (3 inhalatora s 30) doza
English: Patients with severe renal impairment showed no evidence of an increase in systemic exposure to either umeclidinium or vilanterol (Cmax and AUC) following administration of umeclidinium/vilanterol with umeclidinium at twice the recommended dose and vilanterol at the recommended dose and no evidence of altered protein binding between patients with severe renal impairment and healthy volunteers.
Croatian: Oštećenje bubrežne funkcije U bolesnika s teškim oštećenjem bubrežne funkcije nisu pronađeni dokazi povećane sistemske izloženosti ni umeklidiniju ni vilanterolu (Cmax i AUC) nakon primjene doze umeklidinija/vilanterola koja sadrži umeklidinij u dvostruko većoj dozi od preporučene, a vilanterol u preporučenoj dozi, niti dokazi promijenjenog vezanja za proteine u bolesnika s teškim oštećenjem bubrežne funkcije u odnosu na zdrave dobrovoljce.
English: Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics in combination with anticholinergics incl.
Croatian: Farmakoterapijska skupina: Lijekovi za liječenje opstruktivnih bolesti dišnih putova, kombinacije adrenergika i antikolinergika uključujući trostruke kombinacije s kortikosteriodima, ATK oznaka:
English: ELLIPTA 55/22 mcg
Croatian: LAVENTAIR ELLIPTA od 55/22 µg
English: In addition, LAVENTAIR ELLIPTA demonstrated clinically meaningful and statistically significant improvements in trough FEV1 compared with tiotropium in two of the three 6-month active-comparator studies and numerically greater improvements from tiotropium in the third active-comparator study (see Table 1).
Croatian: Osim toga, LAVENTAIR ELLIPTA je u dvama od triju 6-mjesečnih ispitivanja s aktivnim usporednim lijekom doveo do klinički važnih i statistički značajnih poboljšanja najniže vrijednosti FEV1 u usporedbi s tiotropijem te do brojčano većih poboljšanja u usporedbi s tiotropijem u trećem ispitivanju s aktivnim usporednim lijekom
English: Your LAVENTAIR ELLIPTA inhaler carton contains
Croatian: Vaša kutija s LAVENTAIR ELLIPTA inhalatorom sadrži
English: LAVENTAIR ELLIPTA is for inhalation use.
Croatian: LAVENTAIR ELLIPTA namijenjen je za inhalacijsku primjenu.
English: LAVENTAIR ELLIPTA 55/22 micrograms improved exercise endurance time compared with placebo, as evaluated with the endurance shuttle walk test (ESWT), in one study but not the second and improved lung volume measures compared with placebo in both studies in adult COPD patients with hyperinflation (functional residual capacity [FRC] >120%).
Croatian: Primjena lijeka LAVENTAIR ELLIPTA od 55/22 mikrograma u jednom je ispitivanju povećala vrijeme izdržljivosti pri tjelovježbi u usporedbi s placebom, što je ocijenjeno testom izdržljivosti hodanjem u krug (engl. endurance shuttle walk test, ESWT), ali isto nije zabilježeno i u drugome ispitivanju.
English: What LAVENTAIR ELLIPTA is used for
Croatian: Za što se LAVENTAIR ELLIPTA koristi
English: LAVENTAIR ELLIPTA has also shown an improvement in health-related quality of life measured using the St. George's Respiratory Questionnaire (SGRQ) as indicated by a reduction in SGRQ total score at Week 24 compared with placebo and each monotherapy component (see Table 1).
Croatian: St. George's Respiratory Questionnaire, SGRQ), na što ukazuje smanjenje ukupnog SGRQ rezultata nakon 24 tjedna u usporedbi s placebom i svakom od sastavnica u monoterapiji (vidjeti Tablicu 1).
English: Renal impairment No dose adjustment is required in patients with renal impairment.
Croatian: Oštećenje bubrežne funkcije Nije potrebno prilagođavati dozu u bolesnika s oštećenjem bubrežne funkcije.
English: If you get eye pain or discomfort, temporary blurring of vision, visual halos or coloured images in association with red eyes during treatment with LAVENTAIR ELLIPTA:
Croatian: Ako se tijekom liječenja lijekom LAVENTAIR ELLIPTA pojave bol ili nelagoda u oku, privremeno zamagljenje vida, odbljesak ili krugovi duginih boja pred očima (halo efekt) u kombinaciji s crvenilom očiju: Odmah prestanite primjenjivati ovaj lijek i zatražite liječničku pomoć jer bi to mogli biti znakovi akutnog napadaja glaukoma uskog kuta.
English: LAVENTAIR ELLIPTA (N = 207) versus tiotropium 18 mcg (N = 203) (Study DB2113360)
Croatian: LAVENTAIR ELLIPTA (N = 207) naspram tiotropija 18 µg (N = 203) (ispitivanje DB2113360) LAVENTAIR ELLIPTA (N = 217) naspram tiotropija 18 µg (N = 215) (ispitivanje DB2113374)
English: LAVENTAIR ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed umeclidinium/vilanterol
Croatian: LAVENTAIR ELLIPTA 55 mikrograma/22 mikrograma prašak inhalata, dozirani umeklidinij/vilanterol
English: In the three 6-month active-comparator-controlled studies, LAVENTAIR ELLIPTA reduced the use of rescue medication with salbutamol compared with tiotropium, with statistically significant reductions observed in two of the studies (see Table 1).
Croatian: LAVENTAIR ELLIPTA smanjila je uporabu salbutamola kao lijeka za hitno ublažavanje simptoma u usporedbi s tiotropijem, pri čemu su u dvama ispitivanjima opažena statistički značajna smanjenja
English: The maximum mean difference in prolongations of QT interval (corrected using the Fridericia method, QTcF) from placebo after baseline-correction was 4.3 (90% CI=2.2 to 6.4) milliseconds seen 10 minutes after administration with umeclidinium/vilanterol 113/22 micrograms and 8.2 (90% CI=6.2 to 10.2) milliseconds seen 30 minutes after administration with umeclidinium/vilanterol 500/100 micrograms.
Croatian: početnu vrijednost iznosila je 4,3 (90% CI=2,2 do 6,4) milisekunde opaženo 10 minuta nakon primjene umeklidinija/vilanterola u dozi od 113/22 mikrograma te 8,2 (90% CI=6,2 do 10,2) milisekunde opaženo 30 minuta nakon primjene umeklidinija/vilanterola u dozi od 500/100 mikrograma.
English: Placebo (N = 280) LAVENTAIR ELLIPTA (N = 413) versus
Croatian: LAVENTAIR ELLIPTA (N = 413) naspram placeba (N = 280) LAVENTAIR ELLIPTA (N = 413) naspram umeklidinija 55 µg (N = 418)
English: How to store LAVENTAIR ELLIPTA
Croatian: Kako primjenjivati LAVENTAIR ELLIPTA
English: Package leaflet: Information for the user LAVENTAIR ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed umeclidinium/vilanterol This medicine is subject to additional monitoring.
Croatian: Uputa o lijeku: Informacije za korisnika LAVENTAIR ELLIPTA 55 mikrograma/22 mikrograma prašak inhalata, dozirani umeklidinij/vilanterol
English: Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 55 micrograms umeclidinium (equivalent to 65 micrograms of umeclidinium bromide) and 22 micrograms of vilanterol (as trifenatate).
Croatian: Jedna pojedinačna inhalacija osigurava primijenjenu dozu (doza koja izlazi iz nastavka za usta) od 55 mikrograma umeklidinija (što odgovara količini od 65 mikrograma umeklidinijeva bromida) i 22 mikrograma vilanterola (u obliku trifenatata).
English: Vilanterol 22 mcg (N = 421)
Croatian: LAVENTAIR ELLIPTA (N = 413) naspram vilanterola 22 µg (N = 421)
English: What LAVENTAIR ELLIPTA is and what it is used for 2.
Croatian: Što je LAVENTAIR ELLIPTA i za što se koristi
English: LAVENTAIR ELLIPTA is for inhalation use only.
Croatian: Način primjene LAVENTAIR ELLIPTA se primjenjuje isključivo putem inhalacije.
English: LAVENTAIR ELLIPTA demonstrated a statistically significant and clinically meaningful reduction in breathlessness as evaluated by an increase in TDI focal score at Week 24 (key secondary end-point) compared with placebo (see Table 1).
Croatian: LAVENTAIR ELLIPTA je doveo do statistički značajnog i klinički bitnog smanjenja nedostatka zraka, što je ocijenjeno na temelju povećanja ukupnog rezultata Prijelaznog indeksa dispneje (eng.
English: In a pre- and post-natal study, subcutaneous administration of umeclidinium to rats resulted in lower maternal body weight gain and food consumption and slightly decreased pre-weaning pup body weights in dams given 180 micrograms/kg/day dose (approximately 80-times the human clinical exposure of umeclidinium 55 micrograms, based on AUC).
Croatian: 180 mikrograma/kg/dan (izloženost približno 80 puta veća od kliničke izloženosti u ljudi nakon primjene umeklidinija u dozi od 55 mikrograma, što je utvrđeno na temelju AUC-a).
English: triple combinations with corticosteroids, ATC code: R03AL03
Croatian: R03AL03 Mehanizam djelovanja
English: In the second study, LAVENTAIR ELLIPTA 55/22 micrograms showed improvements compared with placebo in change from baseline in lung volume measures at trough and at 3 hours post dose at Week 12 (inspiratory capacity: 198 ml and 238 ml respectively, residual volume: -295 ml and -351 ml respectively and functional residual capacity: -238 ml and -302 ml respectively); all p<0.001∗).
Croatian: LAVENTAIR ELLIPTA od 55/22 mikrograma u 12. tjednu doveo do poboljšanja u usporedbi s placebom s obzirom na promjenu plućnog volumena izmjerenog na kraju intervala doziranja i 3 sata nakon primjene doze u odnosu na početnu vrijednost (udisajni kapacitet: 198 ml odnosno 238 ml,
English: An approximately 1.3-fold increase in umeclidinium AUC was observed at 16-fold higher dose with no effect on umeclidinium Cmax.
Croatian: Pri primjeni šesnaesterostruko veće doze primijećeno je povećanje AUC-a umeklidinija za oko 1,3 puta,
English: An approximately 1.4-fold increase in umeclidinium AUC was observed with no effect on vilanterol AUC.
Croatian: AUC vilanterola nije bilo učinka.
English: Your doctor will tell you how many Olazax tablets to take and how long you should continue to take them.
Croatian: Liječnik će Vam reći koliko Olazax tableta trebate uzeti i koliko ćete ih dugo nastaviti uzimati.
English: Olazax belongs to a group of medicines called antipsychotics and is used to treat the following conditions:
Croatian: Olazax pripada skupini lijekova koji se zovu antipsihotici i koristi se za liječenje sljedećih stanja:
English: If you are pregnant or think you might be pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Croatian: Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
English: Talk to your doctor or pharmacist before you take OLAZAX.
Croatian: Obratite se svom liječniku ili ljekarniku prije nego uzmete lijek Olazax.
English: If you forget to take Olazax Take your tablets as soon as you remember.
Croatian: Ako ste zaboravili uzeti lijek Olazax Uzmite tablete čim se sjetite.
English: What Olazax looks like and contents of the pack
Croatian: Kako Olazax izgleda i sadržaj pakiranja
English: What OLAZAX is and what it is used for
Croatian: Što je OLAZAX i za što se koristi
English: Date of renewal: 22.08.2014
Croatian: Datum posljednje obnove: 11. 12. 2014.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 11.12.2009
Croatian: Datum prvog odobrenja: 11.12.2009.
English: What Olazax is and what it is used for What you need to know before you take Olazax How to take Olazax
Croatian: Što je Olazax i za što se koristi Što morate znati prije nego počnete uzimati Olazax Kako uzimati Olazax
English: (see sections 4.8 and 5.1).
Croatian: (Vidjeti dijelove 4.5 i 5.2.)
English: Other medicines and Olazax
Croatian: Drugi lijekovi i Olazax
English: You should take your Olazax tablets once a day following the advice of your doctor.
Croatian: Olazax tablete morate uzimati jednom dnevno pridržavajući se savjeta svog liječnika.
English: • Moderate to severe manic episodes, a condition with symptoms of excitement or euphoria.
Croatian: • Umjerenih do teških epizoda manije, stanja sa simptomima uzbuđenja ili euforije.
English: Olazax with alcohol
Croatian: Olazaxs alkoholom
English: You should not be given this medicine when breast-feeding, as small amounts of Olazax can pass into breast milk.
Croatian: Ne biste smjeli uzimati ovaj lijek dok dojite, jer se male količine lijeka Olazax mogu izlučiti u majčino mlijeko.
English: In patients with Parkinson's disease Olazax may worsen the symptoms
Croatian: U bolesnika koji boluju od Parkinsonove bolesti, Olazax može pogoršati simptome.
English: Children and adolescents Olazax is not for patients who are under 18 years
Croatian: Djeca i adolescenti Olazax nije za primjenu u bolesnika mlađih od 18 godina.
English: • carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Olazax dose
Croatian: • karbamazepin (antiepileptik i stabilizator raspoloženja), fluvoksamin (antidepresiv) ili ciprofloksacin (antibiotik) - možda će biti potrebno promijeniti dozu lijeka Olazax.
English: It is important that you carry on taking Olazax for as long as your doctor tells you.
Croatian: Važno je da nastavite uzimati lijek Olazax onoliko dugo koliko Vam je liječnik rekao.
English: The daily dose of Olazax is between 5 mg and 20 mg.
Croatian: Dnevna doza lijeka Olazax iznosi između 5 mg i 20 mg.
English: Very common: Weight gain13, elevated triglyceride levels14, increased appetite.
Croatian: Vrlo često: povećanje tjelesne težine13, povišene razine triglicerida14, povećan apetit.
English: Consult your doctor if your symptoms return but do not stop taking Olazax unless your doctor tells you to.
Croatian: Ako Vam se simptomi vrate, posavjetujte se sa svojim liječnikom, ali nemojte prestati uzimati lijek Olazax dok Vam liječnik to ne kaže.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.emea.europa.eu
Croatian: Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove http://www.ema.europa.eu.
English: 1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories.
Croatian: 1 Klinički značajno povećanje tjelesne težine uočeno je u svim početnim kategorijama indeksa tjelesne mase (BMI).
English: What you need to know before you take Olazax
Croatian: Što morate znati prije nego počnete uzimati lijek Olazax
English: Detailed information on this medicine is available on the European Medicines Agency (EMA) website: http://www.emae.europa.eu
Croatian: Detaljnije informacije o ovom lijeku dostupne su na web stranici Europske agencije za lijekove: http://www.ema.europa.eu.
English: If you stop taking Olazax
Croatian: Ako prestanete uzimati lijek Olazax
English: The following symptoms may occur in newborn babies, of mothers that have used OLAZAX in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Croatian: Sljedeći simptomi mogu se pojaviti u novorođenčadi majki koje su koristile lijek Olazax u posljednjem tromjesečju (zadnja tri mjeseca trudnoće): drhtanje, ukočenost mišića i/ili slabost, pospanost, uznemirenost, tegobe s disanjem te poteškoće u hranjenju.
English: • The use of OLAZAX in elderly patients with dementia is not recommended as it may have serious side effects.
Croatian: • Primjena lijeka Olazax u starijih bolesnika s demencijom (zaboravljivošću) se ne preporučuje jer mogu nastati teške nuspojave.
English: Do not drink any alcohol if you have been given Olazax as together with alcohol it may make you feel drowsy.
Croatian: Nemojte piti alkohol ako uzimate lijek Olazax jer u kombinaciji s alkoholom može izazvati omamljenost.
English: Do not take Olazax - If you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6).
Croatian: • Ako ste alergični (preosjetljivi) na olanzapin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: In adult patients who completed 9-12 months of therapy, the rate of increase in mean blood glucose slowed after approximately 6-months.
Croatian: U odraslih bolesnika koji su nakon 9-12 mjeseci završili liječenje, stopa povećanja srednje vrijednosti glukoze u krvi smanjila se nakon približno 6 mjeseci.
English: Olazax 5 mg tablets Olazax 7.5 mg tablets Olazax 10 mg tablets Olazax 15 mg tablets Olazax 20 mg tablets Olanzapine
Croatian: Olazax 5 mg tablete Olazax 7,5 mg tablete Olazax 10 mg tablete Olazax 15 mg tablete Olazax 20 mg tablete olanzapin
English: If this happens after you have been given Olazax, tell your doctor.
Croatian: Vam se ovo pojavi nakon uzimanja lijeka Olazax, obratite se svom liječniku.
English: • Weight gain has been seen in patients taking Olazax.
Croatian: • Zapaženo je povećanje tjelesne težine u bolesnika koji uzimaju lijek Olazax.
English: Olazax, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg are available in aluminium foil blisters of 28 or 56 tablets
Croatian: Olazax 5 mg, 7,5 mg, 10 mg, 15 mg, 20 mg je dostupan u blisterima od aluminijske folije s 28 & 56 tableta.
English: In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α 1 adrenergic; and histamine H1 receptors.
Croatian: U pretkliničkim ispitivanjima olanzapin je pokazao raspon afiniteta za receptore (Ki < 100 nM) serotonina 5HT2A/2C, 5HT3, 5HT6; dopamina D1, D2, D3, D4, D5; kolinergičke muskarinske receptore M1-M5; α1 adrenergičke; i histaminske H1 receptore.